Skip to main content

Table 1 Annual first infection rate, reinfection rate, and HCV treatment coverage observed in the Dat'AIDs cohort between 2012 and 2016

From: Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

  MSM (low-risk/high-risk) Heterosexuals IVDU Others
2012
 First infection rate (per 100 py) 0.02/1.84 0.01 0 0.09
 Reinfection rate (per 100 py) 0.22a/2.56c 0.24b 0.16b 0.27b
 HCV treatment rate (%) 13.4 6.9 6.8 10.9
2013
 First infection rate (per 100 py) 0.06/2.23 0.03 0 0.29
 Reinfection rate (per 100 py) 0.22a/2.56c 0.24b 0.16b 0.27b
 HCV treatment rate (%) 4.4 11.0 5.1 7.6
2014
 First infection rate (per 100 py) 0.12/2.40 0.07 2.13 0.23
 Reinfection rate (per 100 py) 0.22a/2.56c 0.24b 0.16b 0.27b
 HCV treatment rate (%) 10.5 14.0 17.1 23.0
2015
 First infection rate (per 100 py) 0.09/3.42 0.05 1.69 0.17
 Reinfection rate (per 100 py) 0.22a/2.56c 0.24b 0.16b 0.27b
 HCV treatment rate (%) 27.6 36.0 27.0 33.8
  1. aMean yearly reinfection rate observed in non-MSM risk groups between 2012 and 2015
  2. bMean yearly reinfection rate observed in heterosexuals, IVDU, and others risk groups between 2012 and 2015
  3. cMean yearly reinfection rate observed in MSM between 2012 and 2015
  4. HCV hepatitis C virus, IVDU intravenous drug users, MSM men who have sex with men, py person-year